OneMedNet Corporation disclosed that its bookings for the full calendar year 2025 totaled $2.79 million, a 4.1‑fold jump from the $0.68 million recorded in 2024. The surge reflects a combination of larger contract values and a growing pipeline of recurring subscription agreements that replace the company’s earlier project‑based engagements.
The company’s transition to subscription partnerships is a central element of its strategy. In the second and third quarters of 2025, OneMedNet secured agreements with Circle CVI and mlHealth360, both of which are expected to generate recurring revenue streams in 2026. The larger deal sizes underpinning the record bookings are driven by enterprise‑scale AI and life‑sciences engagements that command higher margins than one‑off projects.
OneMedNet’s new subscription offerings—Subscription Search and Subscription Data License—are powered by its integration with Palantir’s AI Platform. The partnership enables near‑real‑time multimodal real‑world data discovery and AI‑driven de‑identification, positioning OneMedNet to capture a growing demand for regulatory‑grade data in drug development and clinical research.
Financially, the company has made significant progress in strengthening its balance sheet. Total liabilities fell from $19.7 million at the end of 2024 to $6.2 million by June 30 2025, an 80 % reduction that frees capital for future growth initiatives and reduces debt‑related risk.
Aaron Green, CEO and President, said, 'This year represents a strategic inflection point for OneMedNet. We are increasing bookings and deal size, and we are successfully transitioning from project‑based engagements to recurring subscription partnerships. This shift enhances visibility, predictability, and long‑term enterprise value.'
Investors reacted positively to the announcement, citing the record bookings and the company’s successful pivot to a subscription model as key drivers of confidence in OneMedNet’s future revenue trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.